which can be dropped into the cellular machinery and can then send back information as to its innermost secrets; it is remarkable that Ehrlich was the first to recognize the special biological importance of the alkylating agents (without, of course, at that time knowing the implications for the cancer problem), since he regarded ethyleneimine as uniquely capable of combining with 'protoplasm', in such a way as might effect irreversible changes in cellular heredity.
The alkylating agents present great advantages in fundamental research and manifest many diverse biological properties. They are highly direct in their action on dividing cells and this action is dependent upon a minimal extent of chemical reactivity. Many are carcinogenic; a feature of the cells of the tumours so induced is often the presence of nuclear andchromosomal anomalies of the same types as those induced by the same agents acting upon normal cells acutely. In general they are also mutagenic and often capable of inducing delicate chromosomal deletions. All these and many other considerations led to the question whether they might act by interference with the normal duplication of the nucleotide chains and certainly the essential question is the nature of the chemical receptor or receptors involved (see Formulary III). Most attention has been devoted to the reactive groups in proteins and nucleoproteins, and the problem was greatly influenced by the proposals of Crick & Watson (1954) for the twin-thread structure of deoxyribonucleic acid. There is no doubt that alkylating agents can effect changes in nucleic acid which are degradative of its essential integrity; a recent important development is the demonstration, by Brookes & Lawley (1960 , 1961 , 1962 , of products in the alkylation of DNA which are almost certainly the result of cross-linkage between guanine moieties in the twin spirals of the nucleic acid helix itself (see Formulary IV). Such reactions could obviously have the most profound effects on the nature and sequence of the purine bases, with major consequences for protein synthesis and the cellular genetics. All these implications are now being studied.
Although no doubt the main effort in cancer research must remain fundamental, as I have tried to show, at the same time there can be limited satisfaction in the development of therapeutic agents by which, even now, we can sometimes prolong comfortable, happy and indeed active life. This must be our purpose and not, as has been said, merely to prolong the act of dying. Of one case it was said by those concerned, 'We lifted the page but we could not turn it'. In the future, no doubt we or our successors will be able not merely to lift the page, but to turn it as well. In the response of cancer to ionizing radiations we are familiar with the term 'radiotherapy', and treatment by means of chemicals may logically be termed 'chemotherapy'. The analogy is particularly close in so far as chemicals which have been shown to have certain 'radiomimetic' properties are being increasingly applied as adjuncts to, or substitutes for, radiotherapy. Since Ehrlich first started his intensive work in 1902, however, the term chemotherapy has been most closely associated with the treatment of protozoal and bacterial infections. These diseases are mainly caused by invasion by a foreign organism, against which the host is able to elaborate defence mechanisms by means of which it may ultimately eradicate entirely the invading organism.
In cancer we are faced with the problem that the 'invading organisms' are cells endogenous to the host that have somehow evaded the normal regulating mechanisms. Woglom (1947) , referring to the difficulties of cancer therapy, said that the problem of treatment is 'almost, not quite but almost, as hard as finding some agent that will dissolve away the left ear, say, yet leave the right ear unharmed, so slight is the difference between the cancer cell and its normal ancestor'. Perhaps today this is unduly pessimistic, indeed radiotherapists might well claim to be able to achieve it, and the recent developments in regional perfusion and infusion techniques with cytotoxic chemicals could go some way towards such an aim. The underlying feeling, however, is that something more than a cytotoxic chemical, perhaps in the nature of localized treatment and nutritional encouragement, may be required to eradicate the cancer and restore normal cell function. We may need more than is defined by the term 'chemotherapy' used in the originalEhrlich conception.
Cancer chemotherapy, however, has in common with the original conception of chemotherapy the necessity of controlling the growthcell divisionof the invading entity. The parallelism is particularly close in the leukemias and lymphomas where the site of origin is not readily localizedindeed may be unknownand the effects are diffuse, so that treatment may have to concern itself in the first instance with attempts to control the output of 'immature' cell forms. This growth control aspect is thus of primary importance here and may to a large extent account for the relative although admittedly limited successes of chemotherapy in control of chronic lymphatic and myeloid leukemia compared to what it has been able to achieve so far in general cancer treatment. If we approach cancer chemotherapy primarily from the standpoint of controlling cell division we are at once faced with the problem that unless we can introduce a high degree of selectivity into our chemicals they will affect unspecifically all tissues which have a high rate of cell division. Such tissues include, for example, intestinal mucosa which is subjected to continuous 'wear' and thus needs a high rate of renewal, and particularly the hxemopoietic system which is concerned with maintaining a continuous high output of mature cells to the circulatory system. It is usually the effects on this systemthe haemotoxicitywhich is the main factor limiting the amount of cytotoxic drug which can be administered to the patient.
In the case of the leukoemias, however, this hemotoxicity can be turned to advantage because the immature leukamic cells are, at the outset of treatment at any rate, usually more sensitive to the cytotoxic agent than are the normal blood cells. A considerable proportion of the chemotherapeutic agents now in clinical use were applied to the treatment of leukaemia after their depressing effects on hmmopoiesis had been observed in preliminary trials against other malignant conditions. In the experimental approaches to cancer chemotherapy the effects of potential therapeutic agents on the circulating blood and on the process of heemopoiesis becomes of fundamental importance for assessing a safe dose against malignant disease in general and, more specifically, as an indicator in selecting compounds for trial against the various forms of leukemia and lymphoma. In our experience it has been found particularly convenient to use the effects on the blood count of the rat in this experimental assessment. Rats have a red cell (erythrocyte) count of up to 10,000,000 per c.mm. Platelets in the rat are also considerably more numerous than in man and are usually of the order of 800,000 per c.mm. The total white cell count varies between about 10,000 and 20,000 cells per c.mm. of which about 20-25 % are neutrophils (polymorphs) and 75-80% lymphocytes. This is almost the reverse of the human pattern where neutrophils may account for about 60-70 % of the total leucocyte count and lymphocytes about 30-40 %. In spite of this reversal the two types of rat leucocyte appear in their response to antileuksrmic agents to behave individually much the same as their human counterparts.
The most useful information, particularly with regard to the mode of action of the different types of cytotoxic chemicals, is being obtained from the blood response patterns to a single dose. To obtain these the percentage change from the normal value (assessed as a mean of at least four rats) is plotted against the time elapsing after administration of a single dose of the chemical.
Blood Response Patterns to Myleran (Busulphan, Formulary VII) and Chlorambucil (Formulary V)
The hmmatological effects of each of thesesubstances imitate to some extent the effects produced by exposure to ionizing radiations and the compounds have hence been described as 'radiomimetic' . Fig 1 shows their blood response patterns compared to that of X-irradiation. The response pattern to Myleran shows an intense prolonged depression of neutrophils and a marked although more delayed depression of platelets. Lymphocytes are only slightly depressed. In contrast to this, in the response to chlorambucil (CB 1348) the greatest depressing effect is seen on the lymphocytes which fall rapidly to a minimum value about four days after administration of a single dose. Neutrophils are nearly as much affected but show a remarkably rapid recovery with overcompensation, so that at about ten days there is marked neutrophilia and the number of circulating neutrophils may be several times the normal value. The excess neutrophils, however, rapidly disappear and normal values are reestablished at fifteen to twenty days. Platelets show a rapid fall, then rapid recovery, but aremuch less affected than with Myleran.
In comparing these response patterns with the effects of whole body X-irradiation it is seen that the platelets behave almost exactly as they do in response to Myleran, whereas the lymphocyte response is remarkably similar to that induced by chlorambucil. The neutrophil response shows features of both Myleran and chlorambucil, and indeed the X-ray response pattern can be remarkably closely reproduced by treatment with a combination of the two drugs. by Galton (1956) . The response curves of the neutrophils (extremely high numbers in the leukeemic patient) and of the platelets, to treatment with Myleran have been replotted as a percentage of the pretreatment blood count values, thus making possible a direct comparison with the blood re-sponse pattern to Myleran in the-normal rat (Fig  1) . The general similarity of the response patterns is very evident. Immature myeloid cells (not represented in Fig 2) which are present in large numbers in the blood before treatment appear to be more sensitive to the drug than the mature Myleran 15mq/kq CH5SO?-CH2CH2CH2CH20 S020C, the lymphocytes, again shows marked similarity to the response pattern of the normal rat to this drug. From the experimental approach of the blood response patterns in the normal rat it seems possible, therefore, to infer to some extent the efficiency of drugs in controlling these chronic forms of leukemia in man. Myleran, which experimentally shows its greatest depressive effects on neutrophils, is able to control myeloid leukemia but is much less efficient against lymphatic leukeemia; the reverse is true of chlorambucil which experimentally shows its greatest effect on lymphocytes and lymphoid organs.
Fig 4 compares the blood response patterns to
Myleran and a dimethyl derivative. The patterns are very similar but dimethyl Myleran is about three times as active as Myleran and is more rapid in its action. The neutrophils reach their minimum values in about eight days compared to about twelve days in the response to Myleran. Recovery is also correspondingly more-rapid. Because of these effects on hbmopoiesis in the normal rat dimethyl Myleran has been used with success' in the clin'ical treatment of leukemia. It is more soluble than Myleran, enabling it to be administered intravenously, and has a more rapid action. Since, however, the main clinical usefulness of Myleran'is in control of chronic myeloid leuktemia it is doubtful-whether these properties give dimethyl Myleran any considerable advantage in treatment of this form of the disease. The antimetabolite 6-thioguanine (closely related to 6-mercaptopurine) has a blood response pattern very similar to that of dimethyl Myleran. An extreme is represented by the compounds aminochlorambucil (see Fig 5) 'and merophan (Formulary VIa).
The leucocyte response patteems are shown in Fig 6. Aminochlorambucil has a much greater effect on lymphocytes than on neutrophils, the ratio of the percentage depression of lymphocytes (L) to that of neutrophils (N) being L/N-= 193. Merophan on the other hand shows a greater effect on neutrophils, L/N=0 6. 
(Reproducedfrom Elson 1963 by kindpermission)
In the effects of a single dose of an antileukemic agent on the blood we can now recognize a 'Myleran type' pattern and two grades, A (Fig 6a) and B (Fig 6 b) , of'nitrogen mustard type' response pattern.
Fig 7 is an attempt. to indicate diagrammatically the effects of these different types of antileukemic chemicals and the effects of X-irradiation on the cell. The 'Myleran type' blood response pattern appears to'result mainly from anmitotic hold up of cells in the haemopoietic system preponderantly of the bone marrow, caused by a prolongation of the intermitotic' interval. Thus the intensity and duration of depression of blood cells depends on the frequency of mitosis of their precursors and orb their life span in the circulation. The greatest depressing effect is seen on the neutrophils and on the platelets.
Compounds giving a 'nitrogen mustard type' response pattern appear to damage mainly those cells of the heemopoietic system which are actually undergoing mitosis or are in the latter part of the premitotic (i.e. the DNA synthetic) period. They also appear to have, to a greater or lesser degree, a direct damaging effect on circulating lymphocytes. With compounds such as aminochlorambucil (see Fig 5) this lymphocytic action appears lg0i-t 't' ;e;; t XD-i~~~~~~~~~~~~~~~t , <; ,X aVO ,, -,,*I-i?! to be extremely marked, resulting in the high L/N ratio in the blood response pattern. This may be termed a grade A nitrogen mustard response. Compounds such as merophan (o-merphalan) (Formulary VIa) on the other hand do not appear to have such a strong direct lymphocytic action and give a grade B nitrogen mustard response pattern. All gradations between these two extremes of lymphocytic action may be found in different nitrogen mustard type compounds. The compound melphalan (Formulary VI) appears to represent a 'half-way house' producing an almost equal fall in lymphocytes and neutrophils (L/N=0 95). The effects of radiation result from prolongation of the intermitotic interval as well as from action on cells in mitosis and on mature circulating lymphocytes. Thus with the antileukwmic chemicals now available we can achieve more selectivity than with radiation. Aminochlorambucil (see Fig  7) for instance is more lymphocytic than radiation, giving a ratio L/N= 193 compared to 1-3 for X-irradiation and 1-6 for the more damaging fast neutrons. By doses of this chemical in rats spaced at about eight-day intervals it is possible to maintain the circulating lymphocytes at a low level with relatively little prolonged effect on neutrophils or platelets. This would seem to be a most useful compound for treatment of chronic lymphatic leukemia; its marked action on circulating lymphocytes, however, does not mean that it is also more effective in suppressing formation of new lymphocytes, normal or leukemic, and clinically it does not appear to have any advantage over chlorambucil (Formulary V) although the best dosage timing to achieve maximum effect has probably not been determined.
Compounds such as merophan (Formulary VIa) show less destructive effect on circulating lymphocytes giving a ratio L/N about 0-6 and their main effect would appear to be focused on cells undergoing mitosis. This is a selectivity of action which is not obtainable with radiation, and compounds of this type would appear to have interesting possibilities. They should have some selective myeloid actionparticularly in suppressing neutrophilsdiffering in mechanism from that of Myleran (Formulary VII), and would be of interest in the clinical treatment of myeloid leukemia. It would, for instance, be worth trying merophan when resistance to Myleran is developing. There may also be a case for combined therapy with Myleran and merophan, and the effect of such combinations on the blood response pattern of the rat is at present being studied.
Another recently developed compound which shows very interesting hwematological effects is mannitol Myleran (Formulary VIII) (Timmis & Brown 1960) . In its body growth-inhibitory action and toxicity in rats, mannitol Myleran behaves more like a nitrogen mustard type compound than a Myleran type (Formulary VII). Toxic doses produce a rapid fall in weight and death from gastro-intestinal symptoms within six days.
Occasionally, however, an animal will survive the gastro-intestinal phase but succumb to a heemorrhagic (Myleran type) death at about fourteen days.
On a weight-for-weight basis mannitol Myleran (Formulary VIII) is very inactive compared with Myleran or the nitrogen mustards. Its activity in the rat is, however, increased about eightfold by prior treatment of the animal with a large dose of glucose. The mechanism of this enhancing effect is not yet completely understood but appears to be mainly due to the induction by the glucose of an extended period of antidiuresis so that the mannitol Myleran, which is normally rapidly excreted, remains at a high level in the blood for a considerable time (Connors & Leese 1963, personal communication) .
The blood response pattern to mannitol Myleran in a rat pretreated with glucose is shown Fig 8. The pattern is mainly that of a grade B nitrogen mustard type response, with the neutrophils being depressed more than the lymphocytes (L/N about 0 75) but it shows a modified hump in the neutrophil response curve similar to that shown inthe response to X-irradiation and a delayed platelet fall characteristic of the response to Myleran and to X-irradiation. Mannitol Myleran thus behaves like a mixture of a Myleranlike component and a grade B nitrogen-mustardlike component, and shows an interesting comparison with X-irradiation which behaves like a mixture of Myleran and a grade A nitrogen mustard (such as chlorambucil). The response pattern is very similar to that of X-irradiation except that the magnitude of the depressive effects on lymphocytes and neutrophils are reversed, Xrays causing the greater effect on lymphocytes, and mannitol Myleran on neutrophils. The dual nature of the response to mannitol Myleran throws an interesting light on its mode of action; experiments are in progress which suggest that it is partially converted in vivo to an epoxide derivative, which is responsible for the nitrogen-mustard-like component of the response pattern which is thus superimposed on the expected Myleran type response of a compound so closely related to Myleran itself.
